Canadanetherlands Ipa Europe Tender

IMMUNOPRECISE ANTIBODIES LTD. the Company or IPA a leader in full-service therapeutic antibody discovery and development announced that its subsidiary IPA Europe has made a substantial investment in its B-Cell Select platform at its research division in Oss The Netherlands enabled by investments in additional equipment to automate and significantly innovate their multi-species target-interaction-based single B-cell selection technology and subsequent single cell cloning thereby significantly accelerating the identification of comprehensive panels of diverse lead therapeutic antibodies. The advanced B Cell Select platform seamlessly integrates into IPAs optimization and antibody developability profiling workflow.Our dedicated and motivated team members are driving the success our B Cell Select platform expansion. This powerful multi-species platform is combined with direct single B cell cloning and antibody binding profiling to rapidly identify highly diverse clinically relevant antibodies to treat various diseases involving a broad variety of complex target antigens. stated Debby Kruijsen General Manager of IPA Europe.Next to its suitability for a broad range of antibody sources our advanced B Cell Select platform is also compatible with various target tools including target-expressing cells enabling us to select clones at an early stage of antibody discovery based on a functional read-out as well. says Ilse Roodink Scientific Director of IPA-EU.